Latest Conference Articles

Ris-rez plus adebrelimab led to an approximate 50% response rate and durable disease control in pretreated nonsquamous NSCLC without actionable mutations.

With approximately 3 years of follow-up, TKI-naive patients with ROS1+ NSCLC experienced long-term benefits with taletrectinib.

Phase 1/2 data from 2 separate studies have shown signals of improved survival and safety with the agent, supporting its evaluation in a phase 3 trial.

Amivantamab plus lazertinib improves second-line PFS vs osimertinib in EGFR-mutant NSCLC, per post hoc data from MARIPOSA presented at AACR 2026.

The brain-penetrant, noncovalent EGFR TKI produced an ORR of 87.5% in 8 efficacy-evaluable patients with EGFR-mutant NSCLC.

The fourth-generation EGFR C797S inhibitor ABK-EGFR-1 showed promising in vivo efficacy in various EGFR C797S mutation models.

Post-treatment ctDNA positivity was associated with disease recurrence in locoregionally advanced HNSCC, including p16-positive oropharynx cancer.

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.

Zoldonrasib produced responses and no grade 4 or 5 TRAEs in previously treated KRAS G12D–mutated NSCLC.

Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.

Gynecologic oncologists share their top data picks from SGO 2026, including ROSELLA, KEYNOTE-B96, NRG-GY019, and more.

Christine M. Lovly, MD, PhD, FASCO, discuses acquired resistance in EGFR-mutated NSCLC, including detection and novel approaches to address it.

Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.

Sac-TMT plus pembrolizumab was safe and effective in recurrent/metastatic cervical cancer.

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

Bradley Monk, MD, discusses the final analysis of the phase 3 KEYNOTE-B96 trial in platinum-resistant recurrent ovarian cancer.

Alexander Olawaiye, MD, discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Significantly improved response rates were shown for liso-cel vs real-world data for SOC in later-line relapsed or refractory mantle cell lymphoma.

ECOG PS should be evaluated before initiating this agent, as patients with poorer PS may experience shorter life expectancy than reported in trials.

Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

The B7-H3–targeting ADC demonstrated encouraging responses across multiple gynecologic cancers in a phase 1/2 trial.

Sun Yang, MD, discusses the activity of frontline cadonilimab plus chemotherapy in patients with recurrent/advanced endometrial carcinoma.

Bhavana Pothuri, MD, discusses phase 2 data with trastuzumab pamirtecan (DB-1303/BNT323) in pretreated patients with HER2-expressing endometrial cancer.

Single-agent rezatapopt showed efficacy and safety irrespective of patients' platinum status, prior bevacizumab or PARP inhibitor exposure, or FRα expression.

Cadonilimab combined with chemotherapy demonstrated robust efficacy and a favorable safety profile in advanced or recurrent endometrial cancer.

Megan Hutchcraft, MD, discusses the use of social media to amplify her online presence in gynecologic oncology research and education.